Fig. 2

The protective effect of ferroptosis inhibitor DFO on EGML

(A) Schematic diagram of the experimental procedures. DFO (30 mg/kg) was intraperitoneally injected into mice before EGML modelling. (B) The mRNA level of HMOX-1, SLC39A14 and ACSL4 in the gastric mucosa. (C) The qRT-PCR and Western blot analysis of TFR1. (D) The macroscopic image of the gastric mucosa. (E) H & E staining. Scale bar = 50 μm. (F) Lipid ROS staining of the gastric mucosa. Scale bar = 100 μm. Data are presented as the mean ± SD. (n = 7–8/group for qRT-PCR). Statistical significance by the one-way ANOVA. *P < 0.05, **P < 0.01